everyone. afternoon, Good
genomic every than as are sequencing rates COVID-XX quickly evolve can are as see These very As based continuing X X, how, Jean-Pierre variant results. for at pace. variants are stated, proportions in a changing any the United faster how weeks, Slide On the predict circulating, reported just why you severe rapid States you see to on and many the there variants further and these which are rates new next surprising to And might disease. that and so of in terms possible infectivity it associated isn't virus. ability can it cause variants come mutations of to RNA evolve other isn't
Not on mutations which XX to contains there of and radar. are is be their level showing the additional unique which further JN.X, is this variants, string. new currently slide that Omnicon reached the compared But of which spread is dominant latest to HV.X XBB.X.X. the The yet of its a hundreds mutation, called yet haven't monitoring appear community on CDC the XX up BA.X.XX variant to more is
game are see, of top become resulted efficacy. from monoclonal the obsolete some and use revoked waning due with is at Each As as quickly mutations with attempts outdated have of variant vaccine apparent have variants of vaccines you authorizations new first-generation can they this, result continued that a monoclonal circulating perpetual impact before On available. introduces that that in often updated catch-up durability. efficacy it Alarmingly, a antibodies seem recently caught can antibodies. we're this, become to to of
of for mutations. the underscores All oral new effective of are this independent role antivirals, direct-acting which important
Importantly, And bemnifosbuvir against this action resistance anticipate to all has we potency mechanism its of unique that variants be the to will to variants a as high tested due new emerge. case maintaining barrier continue to date.
footprint, trial. to our in our enrollment seeing Turning SUNRISE-X Supported promising we're X. global Slide by extensive trends
the use currently need, current clearly to medical concerns, of interactions, due the and drug-drug highlights availability in have patients unmet antiviral XX% agents. globally of of majority This enrollment patient patients monotherapy been oral to important date. tolerability strong enrolled the limit where their and the available sites despite The potential U.S. responsible of arm ongoing clinical safety the in awareness for which to continue approximately continues have We be options. which the
other be U.S. suggests other similarly accounting respiratory hospitals pre-pandemic in pandemic predicted approximately Heading that CDC from winter, any RSV years. high point into half. the hospitalizations than than at more and will COVID-XX account for for those time this this the should half that It's our flu likely worse season and forecast last to where year, full the were of with combined
COVID-XX virus treatment suitable vaccine low of infections with risk the susceptible option. adults, the the vulnerable latest The with only X% and most very U.S. COVID a a to booster underlying which for factors without are approximately uptake to elderly, immunocompromised, severe many severe leaves at infection. There's those the
Slide Turning to X.
focusing patients the approximately as patients, reminder, care analysis X SUNRISE-X review X,XXX primary these we geared interim approximately not towards primary XX, and DSMB's Please supportive is are are care efficacy do is through in a on top endpoint patients initial in There arm line its and or high-risk anticipated the As to DSMB planned hospitalization all-cause the and report analysis also safety results at XXX for day again at death X,XXX year. monotherapy arm. note, review monotherapy in supportive next futility. with data patients expect
April, In which We compelling believe bemnifosbuvir, has absence profile, that bemnifosbuvir were its embryo-fetal differentiated of as good interactions well the the patients. in its as fast the recognized toxicity designation granted reflects the medical unmet clinically track COVID-XX drug with for tolerability and and for we and profile need risk preclinical preclinically both study. of remains for that lower mutagenicity
not whom the and deliver a standard COVID-XX millions care a goal is current suitable patients effective to treatment tolerable this to option. is for of of for safe, Our
opportunity. over to COVID-XX to the I'm to now review the call commercial hand John going
